Glibornuride: Difference between revisions

Revision as of 21:05, 6 April 2015

Template:Chembox header2 \| Glibornuride
Identifiers
CAS Number	26944-48-9^Y
3D model (JSmol)	Interactive image
DrugBank	DB08962^N
ECHA InfoCard	Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
KEGG	D02427^Y
PubChem CID	33649
SMILES CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2C3CCC(C2O)(C3(C)C)C
Properties
Chemical formula	C₁₈H₂₆N₂O₄S
Molar mass	366.48 g/mol
Template:Chembox header2 \| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references

Glibornuride (INN) is an anti-diabetic drug from the group of sulfonylureas.^[1]

↑ Haupt E, Köberich W, Beyer J, Schöffling K (December 1971). "Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects". Diabetologia. 7 (6): 449–54. doi:10.1007/bf01212061. PMID 5004178.

@@ Line 1: / Line 1: @@
-{{chembox
+{{chembox2
 | Verifiedfields = changed
 | UNII_Ref = {{fdacite|correct|FDA}}

v t e Oral antidiabetic drugs and Insulin analogs (A10)
Biguanides	Metformin
Sulfonylureas	Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide
Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose
Thiazolidinediones (TZD)	Pioglitazone, Rivoglitazone^†, Rosiglitazone, Troglitazone^‡
Meglitinides	Nateglinide, Repaglinide, Mitiglinide
Dipeptidyl peptidase-4 (DPP-4) inhibitors	Alogliptin^†, Saxagliptin^†, Sitagliptin, Vildagliptin, Linagliptin^†
Glucagon-like peptide-1 analog	Exenatide, Liraglutide^†, Albiglutide^†
Amylin analog	Pramlintide
Insulin analogs	fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir)
Dual PPAR agonists	Aleglitazar^†, Muraglitazar^§, Tesaglitazar^§
SGLT2 inhibitor	Dapagliflozin^†, Remogliflozin^†
^†Undergoing clinical trials. ^‡ Withdrawn from market. ^§Development halted.